Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Next Science (NXS) has signed a five-year distribution agreement for the sale of its TorrentX Wound Wash in the United States
  • Under the agreement, Tennessee based Triad Life Sciences (TLS) will promote, market, distribute and sell TorrentX in the United States
  • TorrentX is a wound wash for use in places such as emergency rooms, doctor’s offices and ambulances as well as in-home treatment
  • Next Science is up 7.51 per cent on the market today, trading at $1.86 apiece

Next Science (NXS) has signed a five-year distribution agreement for the sale of its TorrentX Wound Wash in the United States.

Under the agreement, Tennessee based Triad Life Sciences (TLS) will promote, market, distribute and sell TorrentX in the United States for the use of wound care for humans.

TorrentX is a wound wash for use in places such as emergency rooms, doctor’s offices, ambulances, pre-hospital treatment rooms and in-home treatment.

In 20 seconds, TorrentX eliminates microbial activity from most wounds.

TLS is also developing a tissue substitute designed to be used for the treatment of both chronic wounds and in surgical care. TLS will be pairing TorrentX with this new skin matrix product.

While awaiting Food and Drug Administration (FDA) 510 (k) clearance of TorrentX and TLS’ skin substitute product, TLS will sell an over-the-counter version of TorrentX on a non-exclusive basis.

Once the clearance is received, TSL will begin exclusive sales of the paired skin substitute and TorrentX under the name ‘TridentX.’

Next Science is up 7.51 per cent on the market today, trading at $1.86 apiece at 3:06 pm AEDT

NXS by the numbers
More From The Market Herald
The Market Herald Video

" Cynata Therapeutics (ASX:CYP) to conclude MEND trial following strategic review

Cynata Therapeutics (ASX:CYP) has completed a strategic review of its clinical development pipeline to maximise commercial…
The Market Herald Video

" AVITA Medical (ASX:AVH) reports positive results from soft tissue trial

AVITA Medical (ASX:AVH) reports positive top line results for its RECELL trial in patients with soft-tissue…
Paradigm Biopharmaceuticals (ASX:PAR) - CEO, Marco Polizzi

" Paradigm Biopharmaceuticals (ASX:PAR) enters trading halt amid cap raise

Paradigm Biopharmaceuticals (ASX:PAR) has entered into a trading halt ahead of a capital raise.
HITIQ (ASX:HIQ) - CEO, Mike Vegar

" HITIQ (ASX:HIQ) secures third Australian innovation patent

HITIQ (ASX:HIQ) has secured a third Australian innovation patent related to its virtual reality (VR) concussion…